Soligenix awards 78,947 stock options to director

A Soligenix director received a new 78,947-share stock option grant at a $0.38 exercise price, vesting through 2027.

Rhea-AI Filing Summary

SOLIGENIX, INC. (SNGX) reported that director Jerome B. Zeldis received a grant of stock options covering 78,947 shares of common stock on September 17, 2026. The options have an exercise price of $0.38 per share, expire on June 16, 2036, and vest in four equal installments from December 17, 2026 through September 17, 2027. No Rule 10b5-1 trading plan is reported for this grant.

Insider Trade Summary

Grant/Award: 78,947 shares

Grant/Award 1 txn

Insider ZELDIS JEROME B

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	78,947	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 78,947 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests ratably on each of December 17, 2026, March 17, 2027, June 17, 2027 and September 17, 2027.

Key Figures

Stock options granted: 78,947 options Exercise price: $0.38 per share Underlying common shares: 78,947 shares +3 more

6 metrics

Stock options granted 78,947 options Director award on September 17, 2026

Exercise price $0.38 per share Exercise price for the 78,947-share option grant

Underlying common shares 78,947 shares Shares of Soligenix common stock underlying the option grant

Options held after transaction 78,947 options Total derivative securities held by the director following the award

Number of vesting installments 4 installments Equal vesting on December 17, 2026; March 17, 2027; June 17, 2027; September 17, 2027

Option expiration date June 16, 2036 Expiration date of the director’s 78,947-share option grant

Key Terms

Stock Option (Right to Buy), Common Stock, exercise price

3 terms

Stock Option (Right to Buy) financial

"Title of derivative security: Stock Option (Right to Buy)"

Common Stock financial

"Underlying security title is reported as Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"The options have an exercise price of $0.38 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SOLIGENIX, INC. (SNGX) report for Jerome B. Zeldis?

Jerome B. Zeldis, a director of SOLIGENIX, INC. (SNGX), received a grant of stock options for 78,947 shares of common stock on September 17, 2026. This is an option award, not an open-market purchase or sale.

What is the exercise price of the new SNGX stock options granted to the director?

The stock options granted to the director have an exercise price of $0.38 per share. This is the price at which the option holder may buy Soligenix common stock upon exercising the options, subject to vesting and before expiration.

When do the newly granted SNGX stock options vest for the director?

The 78,947-share stock option grant vests ratably on four dates: December 17, 2026, March 17, 2027, June 17, 2027, and September 17, 2027. Each date represents an equal portion of the options becoming exercisable.

When do the reported SNGX stock options granted to the director expire?

The stock options granted to the director expire on June 16, 2036. After this expiration date, any unexercised options from this 78,947-share grant will no longer be exercisable.

How many derivative securities does the SNGX director hold after this transaction?

Following the grant, the director holds 78,947 stock options related to Soligenix common stock as reported in this Form 4. These options correspond to an underlying 78,947 shares of common stock if fully vested and exercised.

Were the SNGX director’s option grants made under a Rule 10b5-1 trading plan?

No. The report indicates that no Rule 10b5-1 trading plan is associated with this transaction. The grant is reported as a stock option award without reference to any pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 04:13 PM Accepted by SEC EDGAR 09/18/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZELDIS JEROME B

(Last) (First) (Middle)

C/O SOLIGENIX, INC.

29 EMMONS DRIVE, SUITE B-10

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOLIGENIX, INC. [ SNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.38	09/17/2026		A		78,947		(1)	06/16/2036	Common Stock	78,947	$0	78,947	D

Explanation of Responses:

1. The stock option vests ratably on each of December 17, 2026, March 17, 2027, June 17, 2027 and September 17, 2027.

	/s/ Jerome B. Zeldis	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)